Eton Pharmaceuticals, Inc. announced that it has entered into agreements to issue and sell 1,287,500 shares of common stock at a price of $3.50 per share for gross proceeds of $4,506,250 and to issue pre-funded warrants to purchase an aggregate of 2,462,500 shares of common stock at a price of $3.50 per share for gross proceeds of $8,618,750 for the aggregate gross proceeds of $13,125,000 on April 15, 2024. The Company also entered into an agreement to expand its existing credit facility by $21.9 million to $27.0 million and in connection therewith agreed to issue a warrant to the lender for up to 358,976 shares of common stock at a price of $3.66 per share
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.75 USD | +1.90% | +16.82% | -14.38% |
Apr. 30 | Sector Update: Health Care Stocks Gain in Afternoon Trading | MT |
Apr. 30 | Eton Pharmaceuticals Submits New Drug Application to FDA For ET-400 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.38% | 94.53M | |
+4.30% | 69.17B | |
+12.55% | 9.06B | |
-12.75% | 4.96B | |
+42.38% | 4.47B | |
+5.23% | 3.9B | |
+21.52% | 2.41B | |
-19.05% | 2.41B | |
-28.72% | 2.23B | |
+11.13% | 2.02B |
- Stock Market
- Equities
- ETON Stock
- News Eton Pharmaceuticals, Inc.
- Eton Pharmaceuticals, Inc. announced that it expects to receive $13.125 million in funding